A systematic review of randomized controlled trials reveals some differences in the effects and indications of the three pharmalogical treatments for fibromyalgia. What can prescribing physicians glean from the results?
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Serum proteome profiles revealed dysregulated proteins and mechanisms associated with fibromyalgia syndrome in women
Scientific Reports Open Access 23 July 2020
-
Internet-mediated physiotherapy and pain coping skills training for people with persistent knee pain (IMPACT – knee pain): a randomised controlled trial protocol
BMC Musculoskeletal Disorders Open Access 13 August 2014
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Häuser, W., Petzke, F. & Sommer, C. Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome. J. Pain 11, 505–521 (2010).
Goldenberg, D. L. et al. Durability of therapeutic response to milnacipran treatment for fibromyalgia. Results of a randomized, double-blind, monotherapy 6-month extension study. Pain Med. 11, 180–194 (2010).
Williams, D. A. & Clauw, D. J. Understanding fibromyalgia: lessons from the broader pain research community. J. Pain 10, 777–791 (2009).
Kroenke, K., Krebs, E. E. & Bair, M. J. Pharmacotherapy of chronic pain: a synthesis of recommendations from systematic reviews. Gen. Hosp. Psychiatry 31, 206–219 (2009).
Bjordal, J. M., Klovning, A., Ljunggren, A. E. & Sløordal, L. Short-term efficacy of pharmacotherapeutic interventions in osteoarthritic knee pain: a meta-analysis of randomised placebo-controlled trials. Eur. J. Pain 11, 125–138 (2007).
Chou, R. & Huffman, L. H. Nonpharmacologic therapies for acute and chronic low back pain: a review of the evidence for an American Pain Society/American College of Physicians clinical practice guideline. Ann. Intern. Med. 147, 492–504 (2007).
Williams, D. A. in Fibromyalgia & Other Central Pain Syndromes (eds Wallace, D. J. & Clauw, D. J.) 343–352 (Lippincott Williams & Wilkins, Philadelphia, 2005).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author has acted as a consultant for Cypress Biosciences, Forest Laboratories, Jazz Pharmaceuticals, Lilly, Merck, Pfizer and UCB, and has received research support from Cypress Biosciences, Forest Laboratories and Pfizer.
Rights and permissions
About this article
Cite this article
Clauw, D. Fibromyalgia drugs are 'as good as it gets' in chronic pain. Nat Rev Rheumatol 6, 439–440 (2010). https://doi.org/10.1038/nrrheum.2010.120
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2010.120
This article is cited by
-
Serum proteome profiles revealed dysregulated proteins and mechanisms associated with fibromyalgia syndrome in women
Scientific Reports (2020)
-
Internet-mediated physiotherapy and pain coping skills training for people with persistent knee pain (IMPACT – knee pain): a randomised controlled trial protocol
BMC Musculoskeletal Disorders (2014)
-
Fibromyalgia: from pathophysiology to therapy
Nature Reviews Rheumatology (2011)
-
Web-Based Behavioral Interventions for the Management of Chronic Pain
Current Rheumatology Reports (2011)